Board of Directors
Carol Gallagher, Pharm. D.
NEW ENTERPRISE ASSOCIATES
Carol Gallagher joined New Enterprise Associates (NEA) in October 2014, where she is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA, she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion.
From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Dr. Gallagher raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead has continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
Dennis Henner, PhD
Dennis Henner, Ph.D., has been Managing Director at Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct industry and investment experience within the healthcare sector. From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's Executive Committee. Dr. Henner received his Ph.D. from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Currently Dr. Henner is on the Board of Directors at Cleave Biosciences, CoMentis, Inc., Forty Seven Sciences and Imago BioSciences. Dr. Henner is also a member of the Board of Trustees of Reed College. Past Board seats include Aerie Pharmaceuticals (NASDAQ: AERI), Cellerant, Ceregene, Inc. (acquired by Sangamo BioSciences), Ferrokin Biosciences (acquired by Shire), KaloBios, Pelikan Technologies, Rinat (acquired by Pfizer), Rigel (NASDAQ:RIGL), SARcode (acquired by Shire). Synergia, and Tercica (acquired by Ipsen).
Jonathan Root, MD
US Venture Partners
Jon spent nine years in clinical practice before joining USVP in 1995 as a Ewing Marion Kauffman Fellow in venture capital. He became a general partner in 1997. Before USVP, Jon was on the faculty and clinical staff at The New York Hospital-Cornell Medical Center in New York City. There he was an Assistant Professor of Neurology and Director of the Neurology-Neurosurgery Intensive Care Unit. He is board certified in neurology.
Jon holds an A.B. in Economics from Dartmouth College, an M.D. from the University of Florida, College of Medicine, and an M.B.A. from Columbia University.
Jon is currently on the boards of USVP portfolio companies Cleave Biosciences, eFFECTOR Therapeutics, Inari Medical, Omada Health, OncoMed (Nasdaq: OMED), Sequent Medical and Ribon Therapeutics. Jon is a former board member for the National Venture Capital Association (NVCA).
Alfred Scheidegger, PhD
Founding Partner & CEO
NEXTECH INVEST LTD
Before founding Nextech Invest Ltd. in 1998, Dr. Scheidegger was managing director and member of the board of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. Earlier he served as the first managing director of the Swiss Supercomputing Center (CSCS), and managed an international drug-discovery project at Ciba-Geigy (today Novartis), Japan. He is co-initiator of Venture 98, the first Swiss national business plan contest. Dr. Scheidegger holds a PhD in biochemistry and microbiology from the University of Basel, Switzerland, has completed a post-doctorate research fellowship in enzymology at the University of Kyoto, Japan, and an executive training program at Harvard Business School. He has over 15 years of investment experience in the biotechnology industry.
Currently, Dr. Scheidegger is on the board of directors at Cleave Biosciences, Molecular MD (observer), and Dottikon ES Holding. Past board representations include Agensys (acquired by Astellas), Ganymed Pharmaceuticals, MacroGenics (NASDAQ: MGNX), Sunesis Pharmaceuticals (NASDAQ: SNSS), Tetralogic Pharmaceuticals (NASDAQ: TLOG), and Tracon Pharma (NASDAQ: TCON).
Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Bellerophon (Public), Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (Public), Ikaria (acquired by Madison Dearborn Partners), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, RuiYi, Synosia (acquired by Biotie) and Viveve (Public). Mr. Schwab also serves on the board of the California Academy of Sciences. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.
Laura Shawver, PhD
Chief Executive Officer
Dr. Shawver is an experienced Biotech executive with more than 25 years of experience in the development of small molecule drugs for cancer and other serious diseases. Prior to joining Cleave Biosciences as Chief Executive Officer and driving the $54M Series A financing, she was an Entrepreneur in Residence for 5AM Ventures beginning October 2010. From 2002 - 2010, Dr. Shawver was the Chief Executive Officer of Phenomix Corporation where she also served on the Board of Directors. Phenomix was a venture-backed company that developed dutogliptin through a successful Phase 3 clinical trial and attracted collaborations from Forest Laboratories and Chiesi Farmaceutici. Previously, Dr. Shawver was the President of SUGEN Inc. from 2000 after holding various positions since 1992. SUGEN focused on understanding key molecular pathways of cancer cells and developed the drugs Sutent™ and Palladia™. The company was acquired by Pharmacia in 1999. Prior to SUGEN, she was employed at Berlex Biosciences, formerly known as Triton Biosciences. She is an active member of the American Association for Cancer Research and also a member of American Society for Clinical Oncologists. Dr. Shawver is the Founder of The Clearity Foundation, a nonprofit organization providing access to molecular profiling for ovarian cancer patients to improve their treatment options. Shawver received her PhD in Pharmacology and a BS degree in Microbiology, both from the University of Iowa.
Peter Thompson, MD
Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 25 years of industry experience. Peter co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Cleave Biosciences and Corvus Pharmaceuticals (NASDAQ:CRVS) and was previously an executive of Chiron Corporation and Becton Dickinson. Dr. Thompson also serves as a Director on several public and private company Boards, is an Ernst & Young Entrepreneur of the Year awardee and an Affiliate Professor of Neurosurgery at the University of Washington. He is the inventor on numerous patents is a board-certified internist and oncologist and was on the staff at the National Cancer Institute following his internal medicine training at Yale University.